Semler Scientific Inc. has initiated a Controlled Equity OfferingSM Sales Agreement with several financial institutions, including Barclays Capital Inc. and Cantor Fitzgerald & Co., to raise capital through an at-the-market $(ATM.UK)$ offering program. The company plans to issue and sell up to $500 million of its common stock through this program. As of May 22, 2025, Semler Scientific has successfully issued and sold 3,003,488 shares, generating approximately $114.8 million in net proceeds. This strategic move is part of Semler Scientific's broader efforts to strengthen its financial position.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.